Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.

Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2003;4(2):91-101.

PMID:
12718563
2.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.

Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2004;5(6):315-26.

PMID:
15563234
3.

Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.

Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B.

Integr Cancer Ther. 2004 Sep;3(3):257-61.

PMID:
15312271
4.

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.

Burzynski SR, Janicki TJ, Weaver RA, Burzynski B.

Integr Cancer Ther. 2006 Mar;5(1):40-7.

PMID:
16484713
5.

The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.

Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A.

Childs Nerv Syst. 2014 Dec;30(12):2051-61. doi: 10.1007/s00381-014-2401-z. Epub 2014 Apr 10.

6.

Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al.

Massimino M, Clerici CA.

Childs Nerv Syst. 2014 Dec;30(12):2065-6. doi: 10.1007/s00381-014-2511-7. Epub 2014 Jul 31. No abstract available.

PMID:
25079885
8.

Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.

Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V.

Integr Cancer Ther. 2005 Jun;4(2):168-77.

PMID:
15911929
9.

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.

Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD.

Mayo Clin Proc. 1999 Feb;74(2):137-45.

PMID:
10069350
12.

Quick response of advanced cancer to chemoradiation therapy with antineoplastons.

Tsuda H, Sata M, Kumabe T, Hara H, Eriguchi N, Sugita Y, Nagamatsu H.

Oncol Rep. 1998 May-Jun;5(3):597-600.

PMID:
9538158
13.

Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.

Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y.

Kurume Med J. 1995;42(4):241-9.

14.

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.

Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.

Kurume Med J. 1996;43(2):137-47.

16.

Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study.

Korones DN, Fisher PG, Kretschmar C, Zhou T, Chen Z, Kepner J, Freeman C.

Pediatr Blood Cancer. 2008 Feb;50(2):227-30.

PMID:
17278121
17.

The effect of Antineoplaston, a new antitumor agent on malignant brain tumors.

Sugita Y, Tsuda H, Maruiwa H, Hirohata M, Shigemori M, Hara H.

Kurume Med J. 1995;42(3):133-40.

18.

The preventive effect of antineoplaston AS2-1 on HCC recurrence.

Tsuda H, Sata M, Kumabe T, Uchida M, Hara H.

Oncol Rep. 2003 Mar-Apr;10(2):391-7.

PMID:
12579278
19.

Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.

Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA.

J Neurooncol. 2006 May;77(3):279-84. Epub 2005 Nov 29.

PMID:
16314949
20.

A novel strategy for remission induction and maintenance in cancer therapy.

Tsuda H, Sata M, Ijuuin H, Kumabe T, Uchida M, Ogou Y, Akagi Y, Shirouzu K, Hara H, Nakashima Y.

Oncol Rep. 2002 Jan-Feb;9(1):65-8.

PMID:
11748457
Items per page

Supplemental Content

Write to the Help Desk